| 35 | 0 | 59 |
| 下载次数 | 被引频次 | 阅读次数 |
为发现新型高效GPR52激动剂,本研究以化合物4为苗头化合物,通过骨架跃迁这一经典药物化学手段设计了一系列5-(4-吡啶基)-1H-吡咯-2-甲酰胺类化合物,通过亲核取代反应、Suzuki偶联反应及缩合反应等合成了8个新型GPR52激动剂,并评价了它们的体外GPR52激动活性。其中,化合物6g的激动活性(激活率为93%)与阳性对照化合物4的激动活性(激活率为100%)最接近。分子对接结果表明,化合物6g末端羟基与氨基酸残基Asp38和Thr44均形成氢键相互作用,吡啶环与氨基酸残基Phe300形成π-π堆积作用,而其苯环则伸向疏水口袋形成疏水相互作用。上述实验结果为开发新型高效低毒抗精神分裂症药物奠定了基础。
Abstract:To discover novel and potent GPR52 agonists, compound 4 was used as the hit compound, and a scaffold hopping strategy was applied in this study. Eight novel GPR52 agonists were synthesized via nucleophilic substitution, Suzuki coupling, and amide condensation. Their in vitro GPR52 agonist activities were then evaluated. Among them, the agonistic activity of compound 6g(activation rate of 93%) is closest to that of the positive control compound 4(activation rate of 100%). Molecular docking studies revealed the binding mode of compound 6g. The terminal hydroxyl group formed hydrogen bonds with residues Asp38 and Thr44. The pyridine ring engaged in a π-π stacking interaction with Phe300. The benzene ring extended into a narrow hydrophobic pocket, forming hydrophobic interactions. These findings provide a solid foundation for the development of novel, highly efficacious, and low-toxicity antipsychotic drugs.
[1] McCutcheon R A,Reis Marques T,Howes O D.Schizophrenia—an overview[J].JAMA Psychiatry,2020,77(2):201-210.
[2] Owen M J,Sawa A,Mortensen P B.Schizophrenia[J].The Lancet,2016,388(10039):86-97.
[3] James S L,Abate D,Abate K H,et al.Global,regional,and national incidence,prevalence,and years lived with disability for 354 diseases and injuries for 195 countries and territories,1990—2017:A systematic analysis for the global burden of disease study 2017[J].The Lancet,2018,392(10159):1789-1858.
[4] Kooyman I,Dean K,Harvey S,et al.Outcomes of public concern in schizophrenia[J].British Journal of Psychiatry,2007,191(S50):s29-s36.
[5] Chaiyakunapruk N,Chong H Y,Teoh S L,et al.Global economic burden of schizophrenia:A systematic review[J].Neuropsychiatric Disease and Treatment,2016,12:357-373.
[6] Leucht S,Priller J,Davis J M.Antipsychotic drugs:A concise review of history,classification,indications,mechanism,efficacy,side effects,dosing,and clinical application[J].American Journal of Psychiatry,2024,181(10):865-878.
[7] Kahn R S,Keefe R S E.Schizophrenia is a cognitive illness:Time for a change in focus[J].JAMA Psychiatry,2013,70(10):1107-1112.
[8] Demjaha A,Lappin J M,Stahl D,et al.Antipsychotic treatment resistance in first-episode psychosis:Prevalence,subtypes and predictors[J].Psychological Medicine,2017,47(11):1981-1989.
[9] Strange P G.Antipsychotic drugs:Importance of dopamine receptors for mechanisms of therapeutic actions and side effects[J].Pharmacological Reviews,2001,53(1):119-133.
[10] Stępnicki P,Kondej M,Kaczor A A.Current concepts and treatments of schizophrenia[J].Molecules,2018,23(8):2087-2115.
[11] Solismaa A,Kampman O,Lyytikäinen L P,et al.Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients[J].European Neuropsychopharmacology,2017,27(5):442-449.
[12] Mailman R,Murthy V.Third generation antipsychotic drugs:Partial agonism or receptor functional selectivity?[J].Current Pharmaceutical Design,2010,16(5):488-501.
[13] Lin X,Li M,Wang N,et al.Structural basis of ligand recognition and self-activation of orphan GPR52[J].Nature,2020,579(7797):152-157.
[14] Komatsu H,Maruyama M,Yao S,et al.Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders[J].PLoS One,2014,9(2):e90134.
[15] Setoh M,Ishii N,Kono M,et al.Discovery of the first potent and orally available agonist of the Orphan G-protein-coupled receptor 52[J].Journal of Medicinal Chemistry,2014,57(12):5226-5237.
[16] Nakahata T,Tokumaru K,Ito Y,et al.Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole,a novel series of G protein-coupled receptor 52 (GPR52) agonists[J].Bioorganic & Medicinal Chemistry,2018,26(8):1598-1608.
[17] Ali S,Wang P,Murphy R E,et al.Orphan GPR52 as an emerging neurotherapeutic target[J].Drug Discovery Today,2024,29(4):103922-103931.
[18] Wang P,Felsing D E,Chen H,et al.Discovery of potent and brain-penetrant GPR52 agonist that suppresses psychostimulant behavior[J].Journal of Medicinal Chemistry,2020,63(22):13951-13972.
[19] Poulter S,Austin N,Armstrong R,et al.The identification of GPR52 agonist HTL0041178,a potential therapy for schizophrenia and related psychiatric disorders[J].ACS Medicinal Chemistry Letters,2023,14(4):499-505.
[20] Murphy R E,Wang P,Ali S,et al.Discovery of 3-((4-benzylpyridin-2-yl)amino)benzamides as potent GPR52 G protein-biased agonists[J].Journal of Medicinal Chemistry,2024,67(11):9709-9730.
[21] Yadav M R,Nagaoka M,Kashihara M,et al.The suzuki-miyaura coupling of nitroarenes[J].Journal of the American Chemical Society,2017,139(28):9423-9426.
基本信息:
DOI:10.16441/j.cnki.hdxb.20260035
中图分类号:R914.5
引用信息:
[1]张鹏琪,李梦飞,王平原,等.新型5-(4-吡啶基)-1H-吡咯-2-甲酰胺GPR52激动剂的设计、合成与体外激动活性评价[J].中国海洋大学学报(自然科学版),2026,56(11):77-87.DOI:10.16441/j.cnki.hdxb.20260035.
基金信息:
国家自然科学基金项目(82473839)资助~~
2026-02-05
2026
2026-03-11
2026-04-03
2026
1
2026-10-27
2026-10-27